DISHMAN

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that In reference to Company's intimation dated March 08, 2017, intimation regarding fire took place at one of the units (Unit No.7) at Company's Bavla facility, this is to further inform that there will be no impact on the production in any of the other units located at said Bavla facility.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that there was a fire incident at one of the units (Unit No.7) at the Company's Bavla facility on March 07, 2017 late evening and it had been brought under control. Health and safety of the people is always prime concern and that has been achieved. The Company also do not see any major financial impact due to the incident. Moreover, the Company has an insurance policy for the assets damage and the loss of profit.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company's Bavla facility was successfully inspected by the US FDA in July, 2016, which was intimated to the stock exchanges on July 9, 2016. In this regard, we are pleased to share that the Company has received the Establishment Inspection Report (EIR) from the US FDA for this facility today.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Newspaper Publication of Transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) Suspense Account.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange the newspaper advertisement regarding hearing of petition.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company's wholly owned subsidiary, namely Carbogen Amcis AG., Switzerland, had successfully completed US FDA lnspection for its two sites located at Aarau and Neuland without any adverse observations and received the Establishment lnspection Report (ElR) for the same. Thus, now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA. Additlonally, the company's site at Naroda had also successfully completed USFDA lnspection and received the Establishment lnspect

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange the renewal of US FDA inspection of Company's Bavla facility has been successfully completed on July 08, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding "Transcript of Conference Call".

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Investor Presentation on financial result for the quarter and year ended March 31, 2016 made to Analyst and Investors.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Intimation of Conference Call.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the company has arranged Conference Call with investors on May 20, 2016.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Form A for the Financial Year 2015-2016 as per Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has acquired further 50% stake in Schutz Dishman Biotech Ltd., a Joint Venture Indian Company, from the existing JV Partner i.e. SCHUTZ & CO. BETEILIGUNGSGESELLSCHAFT MBH, Germany for a consideration of EURO 300,000.Schutz Dishman Biotech Ltd. ("Schutz Dishman"), is engaged in the business of manufacturing of Bulk Drugs, Drug formulations and performance Chemicals in India for export markets. Its plant is USFDA approved and is located in the existing campus of Dishman's Bavla manufacturing facility. The sa

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Earnings Conference Call Transcript for quarter and nine months ended December 31, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding a presentation on "Q3 & 9M FY16 Results Update."

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding the Intimation of Analyst /Institutional Investors Meeting held Under SEBI (LODR) Regulation , 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has appointed Dr. Himani Dhotre, most experience Chemist as CEO for its Bavla Plant.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange the details of the authorised persons for the purpose of determining the materiality of any event or transaction or information and for the purpose of making disclosure to Stock Exchange pursuant to Regulation 30(5) of the SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that "Dishman has been awarded manufacture of SIRTURO (bedaquiline) API".

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the e-voting facility for the Extra Ordinary General Meeting to be held on August 14, 2015, is availabe from August 11, 2015 to August 13, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that For the purpose of 31st Annual General Meeting, the Company will provide the e-voting facility to its members in respect of the businesses to be transacted at 31st Annual General Meeting schedule to be held on 4th September, 2014. Therefore, the Company has fixed 25th July, 2014 as cut off date for the purpose of determining the members entitled to vote electronically.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the trading window for the Designated Employees of the Company shall remain close from February 01, 2014 to February 15, 2014 (both days inclusive). During this period, Directors, Designated Employees and their dependents are required not to deal in the shares of the Company.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange vide letter dated October 12, 2013, "Intimation regarding survey conducted by Income Tax Department".

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Company's Wholly Owned Subsidiary company, namely Carbogen Amcis AG., Switzerland has acquired Creapharm Parenterals, a subsidiary of France based Creapharm Group.Creapharm Parenterals is a contract development and manufacturing organization specializing in liquid, semi-solid and injectable aseptic dosage forms. As part of this acquisition, Creapharm Parenterals has changed its name to CARBOGEN AMCIS SAS.The acquisition will extend CARBOGEN AMCIS' comprehensive range of development and manufacturing services by adding

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that company's Wholly Owned Subsidiary company, namely Carbogen Amcis AG., Switzerland has successfully completed US FDA PAI for a new hi potency drug for a US multinational.

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange statement of appropriations as per Clause 20 of the listing agreement.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors, at its meeting held on May 29, 2010, has approved the proposal of issue of further (second trench of) Secured Redeemable Non-Convertible Debentures up to an amount of INR 750 million.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Dishman's Bavla Facilities are approved by Therapeutic Goods Administration (TGA), Department of Health and Ageing, Australian Government, Australia, for all Active Pharmaceutical Ingredients (API) production.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding a strategic alliance with Codexis, Inc., California. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dishman_updates_18022010.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "US FDA team has successfully completed inspection of Dishman's EOU facility situated at its Naroda works, Ahmedabad and approved the said facility for API production for US market".

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding the commissioning of its world-class High containment API facility for manufacture of a range of Oncology APIs and other related high potency products at its Bavla complex, near Ahmedabad. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dishmam_update_21012010.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that :"(1) A new Vitamin-D Analogue facility was inaugurated and started on November 27, 2009 in the facility situated in Veenendaal, the Netherlands, which was acquired by Dishman two years back from Solvay Pharmaceuticals, Netherlands. The total investment in the project is Rs.35 Crores and with this facility, Dishman Netherlands will be the only company in the world having more than Seven Vitamin-D Analogues manufacturing capability. (2) The Pharmaceuticals & Chemicals Special Economic Zone (SEZ) of Dishman Infrastructu

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange information required under Clause 20 of the listing agreement i.e. Statement of Appropriations. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dishman_app_26052009.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "The Board of Directors of the Company has approved a proposal to invest into a formulation facility at the Company's Bavla plant in its meeting held on 30th March, 2009. Purpose of this formulation facility is to become a full service provider as a CRAM Company. Company will invest around Rs.35.00 Crores from cash accruals to create this US FDA and MHRA approvable facility. As per management of the company, Dishman has no plans to enter generic formulation market and this facility is to cater to its customers as a fu

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Dishman Pharma - India and Polpharma - Poland have signed a cooperation and joint API development agreement. Polpharma is in particularly a strong player in its home market and a leader in the Central and Eastern European markets and CIS countries with a turnover of ca 400 million US dollars.The detalis of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/dishman

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: 1) The Company has completed acquisition of land for its Pharmaceutical and Chemical SEZ, near Bavla. Total land acquired for its Pharmaceutical and Chemical SEZ is 390 Acres. Company further announces that land acquisition for its Engineering SEZ is on verge of completion and company will apply for notification of both the SEZ in next 15 to 30 days.Company has appointed a well-known firm,Ms.Multimedia Consultants as their consultant for both the SEZ for planning and engineering activities. Company expects to begin

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange the Audited Financial Results for the year ended March 31, 2008 as required under Clause 20 of the listing agreement i.e. Statement of Appropriations. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dishman_UP_22052008.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "Dishman Pharmaceuticals and Chemicals Ltd. ("the Company") announces that it has completed installation of three API (Active Pharmaceuticals Ingredient) Units at its Bavla facility at around cost of Rs.150 Crores, as "Project Taurus". The last (fourth) API facility will be dedicated for cytotoxic and cytotoxic compounds, such as Anti-Cancer Drugs, Hormones etc. This facility will be ready for commissioning before the end of the current calendar year".